MAIA Stock Forecast: MAIA Biotechnology, Inc. Price Predictions for 2026-2027

Last close, 20 Nov 2026
$1.11
−2.63% on the day

The median 12-month analyst price target for MAIA Biotechnology, Inc. is $12. Ticker Nerd's systematic factor model, run across ~4,300 US stocks, ranks it 40 of 100 as at 21 Nov 2026 — in the lower half.

Market cap
$68.5M
Ticker Nerd rank
40/ 100
Median analyst target
$12
Analysts covering
1
Revenue$0.0
Operating income−$8.1M
Net income−$7.9M
Free cash flow−$6.8M
Quarterly, 8 quarters to 30 June 2026 · latest quarter's figure shown
Total return, dividends reinvested
1W
+11.0%
1M
−0.9%
YTD
−27.5%
1Y
+27.4%
From 52W high
−62.4%
From 52W low
+27.4%
$0.87
$2.95
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

One number for the whole business

Consensus tells you what everyone already believes. The model scores MAIA Biotechnology, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 21 Nov 2026
40/ 100

Percentile across ~4,300 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Volatility
69
Revisions
63
Value
57
Growth
46
Momentum
46
Quality
36
Issuance
26
Accruals
13

Volatility (69): The share price has been relatively steady.

Accruals (13): A large share of reported profit has not shown up as cash, or the balance sheet is expanding quickly — both tend to unwind.

Built and run by Aslam Ghouse, an ex-Goldman Sachs systematic trader with 15+ years in markets.

Wall Street

MAIA stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on MAIA, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$0.00$5.00$10.00$15.00Jan 26Apr 26Jul 26Oct 26MAIAHigh $14Median $12Low $10

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says1 analysts
1
Buy
0
Hold
0
Sell
$10
Low
$12
Median
$14
High
Recent analyst actionsNewest first
DateFirmActionRatingTarget
21 Feb 2023Noble Capital MarketsInitiatesOutperform—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Wall Street targets run 12 to 18 months out. No analyst publishes a 2030 price target for MAIA.

Market Radar

This page is one stock. Monday covers all of them.

MAIA appears in the Radar on the weeks it earns a place.

  • Market Radar, every Monday: the week's biggest rank moves across ~4,300 US stocks, and the reason for each.
  • The AI build-out map, free: every AI company we track on one page, with the model's Top picks in all four parts.

Free. Unsubscribe any time. Privacy

The AI build-out map
PDF
  • AI cloud capacity

    MSFTAMZNGOOGLORCL

  • AI chips

    NVDAAVGOAMDMU

  • AI networking and servers

    ANETDELLLITECRDO

  • Data centre power

    VRTCEGGEVVST

Performance

MAIA vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 20 Nov 2026, MAIA Biotechnology, Inc. returned +27.4% against +6.9% for the S&P 500, dividends included.

MAIA vs S&P 500, last 12 monthsTotal return, rebased to 100
100150200250300Jan 26Apr 26Jul 26Oct 26MAIAS&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

MAIA analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingThis fiscal year
Analysts raising
0
Analysts cutting
1
Fundamentals

Financials

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
—
Price / sales
—
Price / book
4.7×

Cheaper than 20% of US stocks

EV / EBITDA
—
Growth & margins
Revenue growth (YoY)
—
Earnings growth (YoY)
—
Gross margin
—
Operating margin
—
Net margin
—
Returns & dividend
Return on equity
−341.5%

Higher than 4% of US stocks

Return on assets
−101.9%

Higher than 3% of US stocks

Dividend yield
—

Bars mark the percentile across the ~4,300 US stocks Ticker Nerd covers, among those reporting the figure.

Statistics

Key statistics

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • MAIA Biotechnology, Inc. has a market value of $68.5M and an enterprise value of $49.1M.

  • Revenue in the twelve months to 30 June 2026: $0.0.

  • Net income over the same four quarters: −$26.8M.

  • Free cash flow in the twelve months to 30 June 2026: −$22.6M.

  • Shares outstanding: 60.8M.

  • MAIA Biotechnology, Inc. employs 13 people.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 20 Nov 2026

Data provided by Twelve Data

Peers

MAIA and its peers

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelBiotechnology
CompanyMarket capTKN rank
MAIAMAIA Biotechnology, Inc.$68.5M40
PLYXPolaryx Therapeutics, Inc.$66.3M11
PMVPPMV Pharmaceuticals, Inc.$66.1M56
CRDFCardiff Oncology, Inc.$65.7M48
CINGCingulate, Inc.$65.6M25
COYACoya Therapeutics, Inc.$69.2M28
GOSSGossamer Bio, Inc.$65.5M65

Take a look at MAIA’s peer groups, ranked by the model: healthcare stocks · biotech stocks.

Look up any of the roughly 4,300 stocks we score.

The rank is the raw material. Whether the rules would actually own MAIA Biotechnology, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

FAQ

Questions about MAIA

What is the MAIA stock price forecast for 2026-2027?

The median 12-month analyst price target for MAIA Biotechnology, Inc. is $12, with estimates ranging from $10 to $14. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is MAIA stock a buy right now?

Of the 1 analyst covering MAIA Biotechnology, Inc., 1 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks MAIA Biotechnology, Inc. 40 out of 100 across roughly 4,300 US stocks as at 21 Nov 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank MAIA?

As at 21 Nov 2026, MAIA Biotechnology, Inc. ranks 40 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,300 US stocks, built from its factor families. Its strongest factor family is Volatility (69 of 100).

Will MAIA stock go up?

No one can know that. What the data says: the median 12-month target from 1 analyst is $12, and Ticker Nerd's factor model ranks MAIA Biotechnology, Inc. 40 out of 100 as at 21 Nov 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the MAIA stock forecast for 2030?

No analyst covering MAIA Biotechnology, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for MAIA are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $10 to $14 over the next 12 months.

How has MAIA stock performed over the past year?

MAIA Biotechnology, Inc. returned +27.4% over the 12 months to 20 Nov 2026, with dividends reinvested. Past performance does not indicate future returns.

What does MAIA Biotechnology, Inc. do?

MAIA Biotechnology, Inc. is a clinical-stage biopharmaceutical company focused on developing targeted immunotherapies for cancer. MAIA Biotechnology concentrates on oncology programs designed to address telomerase-positive cancers, with its lead asset, ateganosine (THIO), an investigational telomere-targeting agent in clinical development for non-small cell lung cancer.

Company

About MAIA Biotechnology, Inc.

MAIA Biotechnology, Inc. is a clinical-stage biopharmaceutical company focused on developing targeted immunotherapies for cancer. MAIA Biotechnology concentrates on oncology programs designed to address telomerase-positive cancers, with its lead asset, ateganosine (THIO), an investigational telomere-targeting agent in clinical development for non-small cell lung cancer. The company’s work centers on novel mechanisms of action that combine telomere targeting with immunogenic effects, reflecting a precision-medicine approach to difficult-to-treat tumors. MAIA Biotechnology also advances related second-generation telomere-targeting candidates as part of its current research pipeline. Headquartered in Chicago, Illinois and founded in 2018, MAIA Biotechnology operates within the biotechnology sector and plays a specialized role in the cancer therapeutics market by developing experimental treatments intended for use in oncology and immuno-oncology settings.

CEO Dr. Vlad Vitoc M.B.A., M.D. · 13 employees · United States · https://maiabiotech.com